CRAIG MARTIN CREWS, Ph.D.

John C. Malone Professor of Molecular, Cellular, and Developmental Biology
Department of Chemistry
Department of Pharmacology
Yale University

Education

1987-1993 Ph.D., Biochemistry, Harvard University, with Dr. R.L. Erikson (thesis project: Purification/cloning of MEK1)
1986-1987 DAAD Fellow, Universität Tübingen, Germany
1982-1986 B.A., Chemistry, (minor in Biology), University of Virginia

Professional Experience

2019- John C. Malone Professor of Molecular, Cellular, and Developmental Biology
2013 Founder, Arvinas, Inc. (oncology-focused biotech)
2010- Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology
2003 Co-Founder, Proteolix
2003- Executive Director, Yale Small Molecule Discovery Center
2003 PI, NIH T32 Chemistry and Biology Interface (CBI) Training Grant (T32GM067543)
2001-2007 Associate Professor → Professor, Yale University, Dept of Chemistry
1998-2007 Assistant Professor → Professor, Yale School of Medicine, Dept of Pharmacology
1995-2007 Assistant Professor → Professor, Yale University, Dept of Molecular, Cellular & Developmental Biology (tenured 2001)
1993-1995 Postdoctoral Fellow, Dept. of Chemistry, Harvard University, with Dr. Stuart Schreiber

Honors and Awards

2021 Honorary Doctoral Degree, Technische Universität Dortmund, Germany (doctor rerum naturalium honoris causa)
2021 Scheele Prize, Swedish Pharmaceutical Society
2020 Heinrich Wieland Laureate 2020, Boehringer Ingelheim Foundation
2019 American Cancer Society Research Professorship
2019 Pharmacia-ASPET Award for Experimental Therapeutics
2018 Pierre Fabre Award for Therapeutic Innovation
2018 Khorana Prize, Royal Society of Chemistry
2017 AACR Award for Outstanding Achievement in Chemistry in Cancer Research
2015 NIH R35 Outstanding Investigator Award (National Cancer Institute)
2014 UCB-Ehrlich Award for Excellence in Medicinal Chemistry (Eur. Fed. of Med. Chemistry)
2006 Bessel Research Award, Alexander von Humboldt Foundation, Germany

Editorial Boards

Cell Chemical Biology, ACS Chemical Biology, ChemBioChem, Molecular Biosystems, Chemistry & Biology, Molecular and Cellular Proteomics

Patents

'Enzyme Inhibition' Patent US 6,831,099 B1
'Enzyme Inhibition' Patent US 7,476,650
'Proteolysis-Targeting Chimeric Pharmaceutical' Patent US 7,041,298
'Proteolysis-Targeting Chimeric Pharmaceutical' Patent US 7,208,157
'Compounds for Enzyme Inhibition' Patent US 7,232,818
'Compounds for Enzyme Inhibition' Patent US 7,491,704
'Compounds for Enzyme Inhibition' Patent US 8,088,741
'Compounds for Enzyme Inhibition' Patent US 8,129,346

FDA Approved Drugs

Carfilzomib/Kyprolis™ (based on the YU101 structure): approved for relapsed multiple myeloma (7/20/12)


Laboratory Website

http://www.yale.edu/crews

Complete CV